VSC Stock Overview
A biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
4SC AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.01 |
| 52 Week High | €11.20 |
| 52 Week Low | €3.98 |
| Beta | 1.73 |
| 11 Month Change | -11.09% |
| 3 Month Change | -51.10% |
| 1 Year Change | -55.44% |
| 33 Year Change | -22.88% |
| 5 Year Change | -58.12% |
| Change since IPO | -96.37% |
Recent News & Updates
Shareholder Returns
| VSC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.3% | -0.03% | 2.6% |
| 1Y | -55.4% | -21.7% | 4.3% |
Return vs Industry: VSC underperformed the German Biotechs industry which returned -21.7% over the past year.
Return vs Market: VSC underperformed the German Market which returned 4.3% over the past year.
Price Volatility
| VSC volatility | |
|---|---|
| VSC Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: VSC's share price has been volatile over the past 3 months.
Volatility Over Time: VSC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Jason Loveridge | www.4sc.com |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies.
4SC AG Fundamentals Summary
| VSC fundamental statistics | |
|---|---|
| Market cap | €40.56m |
| Earnings (TTM) | -€7.53m |
| Revenue (TTM) | €359.00k |
113.0x
P/S Ratio-5.4x
P/E RatioIs VSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VSC income statement (TTM) | |
|---|---|
| Revenue | €359.00k |
| Cost of Revenue | €73.00k |
| Gross Profit | €286.00k |
| Other Expenses | €7.82m |
| Earnings | -€7.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 17, 2024
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 79.67% |
| Net Profit Margin | -2,097.21% |
| Debt/Equity Ratio | 291.8% |
How did VSC perform over the long term?
See historical performance and comparison